| 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on … RA Nishimura, CM Otto, RO Bonow, BA Carabello, JP Erwin III, ... Circulation 129 (23), e521-e643, 2014 | 9566* | 2014 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2371 | 2019 |
| Efficacy and safety of evolocumab in reducing lipids and cardiovascular events MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ... New England Journal of Medicine 372 (16), 1500-1509, 2015 | 1695 | 2015 |
| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised … FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ... The Lancet 375 (9719), 998-1006, 2010 | 1052 | 2010 |
| A 52-week placebo-controlled trial of evolocumab in hyperlipidemia DJ Blom, T Hala, M Bolognese, MJ Lillestol, PD Toth, L Burgess, R Ceska, ... New England Journal of Medicine 370 (19), 1809-1819, 2014 | 886 | 2014 |
| Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial FJ Raal, N Honarpour, DJ Blom, GK Hovingh, F Xu, R Scott, ... The Lancet 385 (9965), 341-350, 2015 | 852 | 2015 |
| Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study M Cuchel, EA Meagher, H du Toit Theron, DJ Blom, AD Marais, ... The Lancet 381 (9860), 40-46, 2013 | 820 | 2013 |
| ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia JJP Kastelein, HN Ginsberg, G Langslet, GK Hovingh, R Ceska, R Dufour, ... European heart journal 36 (43), 2996-3003, 2015 | 639 | 2015 |
| Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa Clinical Infectious Diseases 73 (7), e2005-e2015, 2021 | 564 | 2021 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 558 | 2019 |
| Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY … CP Cannon, B Cariou, D Blom, JM McKenney, C Lorenzato, R Pordy, ... European heart journal 36 (19), 1186-1194, 2015 | 488 | 2015 |
| Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ... N Engl J Med 372 (16), 1500-1509, 2015 | 470 | 2015 |
| Volanesorsen and triglyceride levels in familial chylomicronemia syndrome JL Witztum, D Gaudet, SD Freedman, VJ Alexander, A Digenio, ... New England Journal of Medicine 381 (6), 531-542, 2019 | 454 | 2019 |
| Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy FJ Raal, GJ Pilcher, VR Panz, HE van Deventer, BC Brice, DJ Blom, ... Circulation 124 (20), 2202-2207, 2011 | 434 | 2011 |
| Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (AMG 145) a pooled analysis of more than 1,300 patients in 4 phase II trials FJ Raal, RP Giugliano, MS Sabatine, MJ Koren, G Langslet, H Bays, ... Journal of the American College of Cardiology 63 (13), 1278-1288, 2014 | 418 | 2014 |
| Triglyceride lowering with pemafibrate to reduce cardiovascular risk A Das Pradhan, RJ Glynn, JC Fruchart, JG MacFadyen, ES Zaharris, ... New England Journal of Medicine 387 (21), 1923-1934, 2022 | 366 | 2022 |
| Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset … FJ Raal, GK Hovingh, D Blom, RD Santos, M Harada-Shiba, E Bruckert, ... The lancet Diabetes & endocrinology 5 (4), 280-290, 2017 | 250 | 2017 |
| PCSK9 inhibition-mediated reduction in Lp (a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role [S] FJ Raal, RP Giugliano, MS Sabatine, MJ Koren, D Blom, NG Seidah, ... Journal of lipid research 57 (6), 1086-1096, 2016 | 222 | 2016 |
| Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance M Agostini, E Schoenmakers, C Mitchell, I Szatmari, D Savage, A Smith, ... Cell metabolism 4 (4), 303-311, 2006 | 217 | 2006 |
| Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ... The Lancet 398 (10312), 1713-1725, 2021 | 189 | 2021 |
F J RaalProfessor, University of the Witwatersrand在 wits.ac.za 的电子邮件经过验证
